Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Non-Current Debt (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Non-Current Debt for 11 consecutive years, with $961.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 477.78% to $961.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $961.9 million through Dec 2025, up 477.78% year-over-year, with the annual reading at $961.9 million for FY2025, 477.78% up from the prior year.
  • Non-Current Debt for Q4 2025 was $961.9 million at BeOne Medicines, up from $832.8 million in the prior quarter.
  • The five-year high for Non-Current Debt was $961.9 million in Q4 2025, with the low at $146.1 million in Q2 2025.
  • Average Non-Current Debt over 5 years is $262.4 million, with a median of $200.0 million recorded in 2021.
  • Peak annual rise in Non-Current Debt hit 477.78% in 2025, while the deepest fall reached 21.15% in 2025.
  • Over 5 years, Non-Current Debt stood at $202.1 million in 2021, then grew by 3.48% to $209.1 million in 2022, then dropped by 5.51% to $197.6 million in 2023, then fell by 15.75% to $166.5 million in 2024, then skyrocketed by 477.78% to $961.9 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $961.9 million, $832.8 million, and $146.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.